Literature DB >> 11758871

Spectroscopy in prostate cancer: hope or hype?

M Roach1, J Kurhanewicz, P Carroll.   

Abstract

Clinical applications of image-based radiation therapy for the study of prostate cancer have expanded significantly over the past years. The results of recent studies of magnetic resonance imaging (MRI) combined with magnetic resonance spectroscopic imaging (MRSI) demonstrate that the MRI/MRSI exam is a unique method by which to noninvasively study the cellular metabolism and anatomy of the prostate. This technology has the potential to define the tumor volume through functional or metabolic imaging. The results of current MRI/ MRSI studies also provide evidence that the magnitude of metabolic changes in regions of cancer before therapy, as well as the extent of the time course of metabolic changes after therapy, may improve our understanding of cancer aggressiveness. Assessment of cancer spread outside the prostate can be significantly improved by combining MRI findings with estimates of metabolic abnormalities provided by MRSI. Clinically, combined MRI/MRSI has already demonstrated a potential for improved diagnosis, staging, and treatment planning for patients with prostate cancer. Additional studies will reveal both the positive aspects and clinical challenges of MRI/

Entities:  

Mesh:

Year:  2001        PMID: 11758871

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  9 in total

Review 1.  Molecular imaging for personalized cancer care.

Authors:  Moritz F Kircher; Hedvig Hricak; Steven M Larson
Journal:  Mol Oncol       Date:  2012-03-10       Impact factor: 6.603

2.  Multiparametric 3T endorectal mri after external beam radiation therapy for prostate cancer.

Authors:  Antonio C Westphalen; Galen D Reed; Phillip P Vinh; Christopher Sotto; Daniel B Vigneron; John Kurhanewicz
Journal:  J Magn Reson Imaging       Date:  2012-04-25       Impact factor: 4.813

Review 3.  Advances in MR spectroscopy of the prostate.

Authors:  John Kurhanewicz; Daniel B Vigneron
Journal:  Magn Reson Imaging Clin N Am       Date:  2008-11       Impact factor: 2.266

Review 4.  Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer.

Authors:  John Kurhanewicz; Mark G Swanson; Sarah J Nelson; Daniel B Vigneron
Journal:  J Magn Reson Imaging       Date:  2002-10       Impact factor: 4.813

Review 5.  The role of metabolic imaging in radiation therapy of prostate cancer.

Authors:  V Y Zhang; A Westphalen; L Delos Santos; Z L Tabatabai; K Shinohara; D B Vigneron; J Kurhanewicz
Journal:  NMR Biomed       Date:  2013-08-12       Impact factor: 4.044

6.  Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294.

Authors:  Kiaran P McGee; Ken-Pin Hwang; Daniel C Sullivan; John Kurhanewicz; Yanle Hu; Jihong Wang; Wen Li; Josef Debbins; Eric Paulson; Jeffrey R Olsen; Chia-Ho Hua; Lizette Warner; Daniel Ma; Eduardo Moros; Neelam Tyagi; Caroline Chung
Journal:  Med Phys       Date:  2021-05-20       Impact factor: 4.071

7.  Progress in the imaging of the prostate gland.

Authors:  J P M Sedelaar; J J M C H de la Rosette; F M J Debruyne
Journal:  Curr Urol Rep       Date:  2003-02       Impact factor: 2.862

Review 8.  Three-dimensional conformal brachytherapy for prostate cancer.

Authors:  Michael J Zelefsky
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 2.862

9.  NIR-Cyanine Dye Linker: a Promising Candidate for Isochronic Fluorescence Imaging in Molecular Cancer Diagnostics and Therapy Monitoring.

Authors:  Dorde Komljenovic; Manfred Wiessler; Waldemar Waldeck; Volker Ehemann; Ruediger Pipkorn; Hans-Hermann Schrenk; Jürgen Debus; Klaus Braun
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.